Travere Therapeutics
TVTX

Travere Therapeutics (TVTX) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
Evercore ISI GroupMaintainedOutperform$78.00 from $68.00Aug 10, 2026
WedbushMaintainedOutperform$75.00 from $61.00Aug 6, 2026
Canaccord GenuityMaintainedBuy$70.00 from $62.00Aug 6, 2026
GuggenheimMaintainedBuy$75.00 from $65.00Aug 5, 2026
Evercore ISI GroupMaintainedOutperform$68.00 from $60.00Aug 5, 2026
CitigroupMaintainedBuy$85.00 from $70.00Aug 5, 2026
TD CowenMaintainedBuy$75.00 from $60.00Aug 5, 2026
Canaccord GenuityMaintainedBuy$62.00 from $56.00Jul 30, 2026
GuggenheimMaintainedBuy$65.00 from $56.00Jun 25, 2026
WedbushMaintainedOutperform$61.00 from $55.00Jun 22, 2026
Evercore ISI GroupMaintainedOutperform$60.00 from $52.00Jun 18, 2026
CitigroupMaintainedBuy$70.00 from $62.00Jun 15, 2026
Wells FargoMaintainedOverweight$65.00 from $50.00Jun 12, 2026
WedbushMaintainedOutperform$55.00Jun 3, 2026
CitigroupMaintainedBuy$62.00 from $59.00Jun 3, 2026
HC Wainwright & Co.MaintainedBuy$67.00 from $57.00Jun 2, 2026
Wells FargoMaintainedOverweight$50.00 from $40.00May 6, 2026
HC Wainwright & Co.MaintainedBuy$57.00 from $47.00May 5, 2026
WedbushMaintainedOutperform$55.00 from $53.00May 5, 2026
CitigroupMaintainedBuy$59.00 from $53.00May 5, 2026

Frequently asked questions

  • What is the latest analyst rating on TVTX?

    On Aug 10, 2026, Evercore ISI Group maintained Travere Therapeutics at Outperform with a price target of $78.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.